Graffinity and Amgen in research deal
Germany-based Graffinity Pharmaceuticals has entered into a research collaboration with Amgen of Thousand Oaks, California for the generation of novel small molecule hits against a broad range of drug targets.
Germany-based Graffinity Pharmaceuticals has entered into a research collaboration with Amgen of Thousand Oaks, California for the generation of novel small molecule hits against a broad range of drug targets.
For an unspecified fee, Amgen will gain access to Graffinity's proprietary fragment-based drug discovery technology which uses chemical microarrays to screen for small molecule fragments that bind to a variety of drug targets which play a key role in major human diseases.
The identification of novel modes of action and chemistry is a major focus of the collaboration. Financial details of the transaction were not disclosed.